Literature DB >> 8198706

Inadequate epidermal homing leads to tissue damage in human cutaneous leishmaniasis.

F J Tapia1, G Cáceres-Dittmar, M A Sánchez.   

Abstract

Leishmaniasis is a model disease for the study of immunoregulatory mechanisms associated with host resistance and susceptibility. In this article, Felix Tapia and colleagues propose that defects in the signaling properties of the epidermis can result in the generation of either a chronic granulomatous response, which is unable to eliminate the parasite, or a proinflammatory mucocutaneous response and tissue damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198706     DOI: 10.1016/0167-5699(94)90312-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  5 in total

Review 1.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.

Authors:  D M Isaza; M Restrepo; W Mosca
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

3.  Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic.

Authors:  Fadile Yildiz Zeyrek; Metin Korkmaz; Yusuf Ozbel
Journal:  Clin Vaccine Immunol       Date:  2007-08-29

4.  Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis.

Authors:  Jiaxiang Ji; Jiaren Sun; Lynn Soong
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

5.  Histopathological characteristics of cutaneous lesions caused by Leishmania Viannia panamensis in Panama.

Authors:  Kadir González; Rosendo Diaz; Aurea F Ferreira; Víctor García; Héctor Paz; José E Calzada; Michelle Ruíz; Márcia Laurenti; Azael Saldaña
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-02-15       Impact factor: 1.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.